Rheumatoid Arthritis Drugs Market to Reach US$56.62 Billion by 2033, Growing at 6.8% CAGR | Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Segment Leads with 45.1% Market Share | DataM Intelligence

Leander, Texas and Tokyo, Japan - Dec 03, 2025
According to DataM Intelligence, the global rheumatoid arthritis drugs market size reached US$31.27 billion in 2024 and is expected to reach US$56.62 billion by 2033, growing at a CAGR of 6.8% during the forecast period 2025-2033. This steady growth is propelled by the rising global prevalence of rheumatoid arthritis (RA), increasing adoption of biologic and targeted synthetic DMARDs, growing geriatric population, advancements in personalized medicine and biomarker-driven therapies, and expanding treatment access in emerging economies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/rheumatoid-arthritis-drugs-market?jd

Report Details:
• No. of Pages: 180
• Forecast Period: 2025-2033
• Market Size (2024): $31.27 Billion
• Market Size (2033): $56.62 Billion
• Compound Annual Growth Rate: 6.8%
• Regions Covered: Global

Global Recent Developments:
✅ November 2025: AbbVie Inc. received FDA approval for its next-generation JAK inhibitor, a highly selective TYK2 inhibitor, with a superior cardiovascular safety profile compared to first-generation JAK drugs, poised to capture significant market share within the JAK Inhibitors class.
✅ November 2025: Amgen Inc. launched a comprehensive digital companion app for its RA portfolio, integrating symptom tracking with medication reminders and telehealth access, aimed at improving adherence for drugs administered via the Parenteral route.
✅ October 2025: Bristol-Myers Squibb Company and Pfizer Inc. faced the first US launch of a high-concentration, citrate-free biosimilar for their blockbuster drug Enbrel (etanercept), triggering a price war in the TNF-inhibitor segment of Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and increasing patient access.
✅ October 2025: Regeneron Pharmaceuticals, Inc. and Sanofi announced positive long-term data for their IL-6 inhibitor, Kevzara, showing sustained remission and prevention of radiographic progression, strengthening its position as a core biologic DMARD.
✅ September 2025: Eli Lilly and Company presented groundbreaking Phase 3 data for an oral BTK inhibitor demonstrating efficacy in patients refractory to both TNF inhibitors and JAK inhibitors, potentially creating a new line of therapy within the DMARDs category.

Buy Now and Enjoy a 30% Year-End Discount: https://www.datamintelligence.com/buy-now-page?report=rheumatoid-arthritis-drugs-market

Competitive Landscape
The market is highly competitive, dominated by a few key players with deep immunology portfolios, with biosimilars rapidly changing the landscape.

1. AbbVie Inc. maintained its market leadership, primarily driven by Humira (adalimumab), though facing biosimilar erosion, and the strong growth of its newer agents Skyrizi (IL-23) and Rinvoq (JAK inhibitor).
2. Amgen Inc. and Pfizer Inc. (via the Enbrel partnership) held a major share, though their position is under intense pressure from multiple Enbrel biosimilars entering the US market in 2025.
3. Johnson & Johnson (Janssen Biotech, Inc.) remained a leader with its IL-12/23 inhibitor Stelara and its newer IL-23 inhibitor Tremfya, maintaining a strong pipeline.
4. Bristol-Myers Squibb Company held significant share with Orencia (abatacept) and its newer TYK2 inhibitor.
5. Eli Lilly and Company and Regeneron Pharmaceuticals, Inc. were key innovators, with Lilly growing its share through Olumiant (baricitinib) and pipeline assets, and Regeneron through Kevzara (sarilumab).

Speak to Our Analyst and Get Customization in the Report: https://www.datamintelligence.com/customize/rheumatoid-arthritis-drugs-market?jd

Segmentation Analysis
By Drug Class
• Based on drug class, disease-modifying anti-rheumatic drugs (DMARDs) segmented the market with the largest revenue share of 45.1% in 2024. This segment includes conventional synthetic DMARDs (e.g., methotrexate), biologic DMARDs (e.g., TNF inhibitors, IL-6 inhibitors), and targeted synthetic DMARDs (e.g., JAK inhibitors). It is the cornerstone of RA treatment, as it alters the disease course rather than just alleviating symptoms.
• JAK Inhibitors are the fastest-growing sub-segment within DMARDs, despite safety concerns, due to their oral administration and efficacy.

By Route of Administration
• Parenteral (subcutaneous or intravenous injection/infusion) routes dominate in terms of revenue, as most high-cost biologic DMARDs are administered this way.
• Oral administration is growing rapidly, driven by the success and pipeline of JAK inhibitors and other small molecules, favored for patient convenience.

By Distribution Channel
• Hospital Pharmacies are a key channel for infused therapies and complex patient management.
• Retail Pharmacies and Online Pharmacies are major channels for oral medications (NSAIDs, corticosteroids, JAK inhibitors) and self-administered injectables, with online pharmacies gaining significant traction for refills and direct-to-patient biologic services.

Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription?jd

Regional Analysis:
North America dominates the rheumatoid arthritis drugs market with the largest revenue share of 43.5% in 2024. This is driven by high drug prices, favorable reimbursement policies, early adoption of novel biologics and JAK inhibitors, a well-established diagnostic infrastructure, and a high prevalence of RA.
The Asia Pacific is the fastest-growing region and is expected to grow at the fastest CAGR of 8.1% over the forecast period. Growth is fueled by the large patient population, improving healthcare access and diagnosis rates, increasing affordability due to biosimilar penetration and local manufacturing, and rising healthcare expenditure.

Market Trends & Drivers
The RA drugs market is characterized by a shift towards more targeted, convenient, and safer therapies. Key trends include the transformative impact of biosimilars, driving down costs and increasing access to biologic DMARDs; the development of next-generation JAK inhibitors with improved safety profiles; increased focus on treat-to-target and precision medicine approaches using biomarkers; and the growth of subcutaneous formulations for drugs previously requiring infusion. The aging population, biosimilar-driven market expansion, and ongoing innovation in targeted therapies are the primary market drivers.

Related Reports:
1. Autoimmune Treatment Market - https://www.datamintelligence.com/research-report/autoimmune-treatment-market?jd
2. Biosimilars Market - https://www.datamintelligence.com/research-report/biosimilars-market?jd
3. Orphan Drugs Market - https://www.datamintelligence.com/research-report/orphan-drugs-market?jd

Contact Us:
Sai Kiran
DataM Intelligence 4market Research LLP
Phone: +1 877-441-4866
Email: Sai.k@datamintelligence.com

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specialises in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.

This release was published on openPR.